Cancer drug Avastin may work as imaging tool too

LONDON (Reuters) - Genentech and Roche’s cancer drug Avastin can help find tumors as well as treat them, scientists said on Wednesday.

After tagging the antibody drug with a radioactive tracer and injecting it into mice, researchers found it successfully targeted cancer cells and this enabled them to produce well-defined images of tumors during scanning.

When compared with images of the same tumors taken using standard imaging, the Avastin images were better and also showed up tumors in earlier stages and at smaller sizes.

The research was presented at a EORTC-NCI-AACR conference on cancer in Geneva by Zheng Jim Wang, director of molecular imaging at privately owned company MPI Research Inc and an assistant professor at the University of Texas Health Science Center at San Antonio.

Scientists need to confirm their discovery in further studies and clinical trials but Wang hopes the new technique will eventually help doctors detect and diagnose tumors at earlier stages, improving treatment outcomes.

Avastin or bevacizumab — a blockbuster treatment used mainly in bowel cancer — is a so-called targeted therapy that works by starving tumors of blood supply. It had sales of 4.1 billion Swiss francs ($3.6 billion) last year.

Wang said it was possible that other targeted cancer therapies could be used for imaging in a similar way, but this depended on the type and biological distribution of the drug.

(Reporting by Ben Hirschler; Editing by Quentin Bryar)


Related Posts:

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Combining two chemotherapy drugs with two targeted therapies was safe and appeared to help patients with advanced lung cancer live longer, U.S. researchers reported on Thursday. The combination of Roche and Co’s Avastin, ImClone’s Erbitux, carboplatin and paclitaxel appeared to add an average of two months to

Full Post: Four drug combination helps in lung cancer: U.S. study

* Avastin meets goal in breast cancer clinical trial * Study shows Avastin can be added to common chemotherapies * Roche stock up 4.1 percent ZURICH (Reuters) - Roche Holding AG, the world’s largest maker of cancer drugs, said on Monday that Avastin met its primary endpoint in a Phase III breast cancer trial. Roche said Avastin, which it

Full Post: Study boosts Roche’s Avastin in breast cancer

WASHINGTON (Reuters) - A new type of imaging compound can literally light up spreading cancer cells and may offer a way to track the deadly spread of the disease, Japanese and U.S. researchers reported on Sunday. They used the new compound to monitor the spread of breast and ovarian cancer cells in living mice, using a

Full Post: Compound lights up spreading cancer cells

LONDON (Reuters) - Scientists have uncovered a second gene mutation that determines which patients will respond to the bowel cancer drugs Erbitux and Vectibix, opening the way to still more targeted treatment. Treating patients based on their genetic make-up is a growing trend in oncology, and the latest research, reported at a medical meeting in Geneva

Full Post: New gene mutation linked to cancer drugs’ success

FRANKFURT (Reuters) - Merck KGaA said on Wednesday a Phase II trial provided further evidence that its cancer drug Erbitux was particularly effective at fighting bowel tumors whose cells did not undergo a certain type of genetic mutation. The German drugs and chemicals maker said that 53 percent of patients who did not have a mutation

Full Post: Merck says study confirms efficacy of Erbitux drug

Site Navigation

Most Read